Nerviano Medical Sciences (NMS) is a clinical-stage oncology company with global operations in Milan, Italy, Boston, USA and Shanghai, China. With a long legacy rooted in Italian pharmaceutical innovation, NMS specializes in the discovery and development of small molecules and Antibody Drug Conjugates (ADCs) targeting novel mechanisms of action in cancer. Our unique platforms—spanning Kinase inhibitors, DNA Damage Response (DDR), and proprietary payload-linker technologies—enable the creation of first- and best-in-class precision therapies.

We have a proven track record of advancing assets from bench to clinic and partnering with global pharma. Notable successes include out-licensing and royalty agreements for compounds like Entrectinib (Rozlytrek®), Encorafenib (Braftovi®) and Onvansertib.